Current U.S. ICLUSIG labeling lists 10 mg, 15 mg, 30 mg and 45 mg tablets.
The Ponaxen website brief identifies 15 mg and 45 mg strengths. Ponaxen-specific packaging and authorization should be verified before publishing any statement about its commercially available dosage units.
| Strength | Current U.S. ICLUSIG label | Ponaxen website identification |
|---|---|---|
| 10 mg | Yes | – |
| 15 mg | Yes | 15 mg |
| 30 mg | Yes | – |
| 45 mg | Yes | 45 mg |
Strength does not by itself determine the correct dose. For example, current U.S. labeling uses a 45 mg starting dose for several treatment settings but a 30 mg starting dose for newly diagnosed Ph+ ALL in combination with chemotherapy.
Why multiple strengths matter
Different strengths can facilitate dose modification. Ponatinib treatment may involve reductions because of treatment response or adverse reactions.
Product verification
The exact strength printed on a Ponaxen package should be checked against the prescription, product documentation and applicable regulatory information.